Table 1.
Clinical and biochemical features of our patients
| Case 1 | Case 2 | Case 3 | |
|---|---|---|---|
| Age (years) | 50 | 55 | 61 |
| Sex | M | F | M |
| Clinical presentation | Fatigue, palpitations, distal tremor, insomnia, anxiety, nervousness and irritability | Fatigue, tremors and palpitations | Fatigue and muscle weakness, decreased concentration, loss of memory, depression, increased sensitivity to cold, constipation |
| Time to onset of symptoms after vaccination (days) | 14 | 10 | 15 |
| Personal history of autoimmune disease | No |
Yes HT |
Yes GD |
| Family history of autoimmune disease | Yes | Yes | Yes |
| TFTs | |||
| At onset of symptoms | |||
| TSH (IUml) | 0.001 | 0.006 | 37.97 |
| FT4 (ng/dl) | 2.0 | 4.56 | 0.56 |
| FT3 (pg/ml) | 10.47 | 6.82 | 2.0 |
| Tg-Ab (IU/l) | 385.49 | 11.0 | 356 |
| TPO-Ab (IU/l) | 529.50 | 344 | 1590 |
| TRAB (IU/l) | 5.0 | < 1.0 | – |
| At follow-up six months later | |||
| TSH (IU/l) | 1.06* | 10.8 | 2.45# |
| FT4 (ng/dl) | 0.92 | 0.80 | 1.1 |
| FT3 (pg/ml) | 3.58 | 2.4 | 2.78 |
HT Hashimoto’s thyroiditis, GD Graves’ disease, TFTs Thyroid Function Tests, TSH Thyroid stimulating hormone (normal values: 0.25–4.5), FT3 free Triiodothyronine (n. 2.0–4.0), FT4 free Thyroxine (n.v. 0.7–1.48), TRAb Thyrotropin receptor antibody (n.v. < 1.0), Anti-TPO Anti-Thyroid peroxidase antibodies (n.v. 0–10), Tg-Ab anti-thyroglobulin antibodies (n.v. 0–40)
*Under methimazole therapy, #under L-Thyroxine therapy